Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Vumon (teniposide)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

BMS

Drug class:

Topoisomerase II inhibitor

Related drugs:

doxorubicin hydrochloride (87)

etoposide IV (53)

etoposide oral (33)

pegylated liposomal doxorubicin (31)

epirubicin (29)

daunorubicin (20)

cytarabine/daunorubicin liposomal formulation (19)

idarubicin hydrochloride (16)

mitoxantrone (16)

dactinomycin (8)

non-pegylated liposomal doxorubicin (3)

pegylated liposomal doxorubicin (1)

zoptarelin doxorubicin (1)

mitoxantrone liposomal (0)

H-ferritin–nanocaged doxorubicin (0)

non-pegylated liposomal doxorubicin (0)

lyso-thermosensitive liposomal doxorubicin (0)

tirapazamine (0)

dexrazoxane (0)

doxorubicin liposomal (0)

›

TOP2A overexpression	Adrenal Cortex Carcinoma	TOP2A overexpression	Adrenal Cortex Carcinoma	teniposide Sensitive: D – Preclinical teniposide Sensitive : D	teniposide Sensitive: D – Preclinical teniposide Sensitive : D
IDH2 mutation	Glioma	IDH2 mutation	Glioma	teniposide Sensitive: D – Preclinical teniposide Sensitive : D	teniposide Sensitive: D – Preclinical teniposide Sensitive : D
IDH1 mutation	Glioma	IDH1 mutation	Glioma	teniposide Sensitive: D – Preclinical teniposide Sensitive : D	teniposide Sensitive: D – Preclinical teniposide Sensitive : D
TOP2A overexpression	Rectal Cancer	TOP2A overexpression	Rectal Cancer	teniposide Resistant: D – Preclinical teniposide Resistant : D	teniposide Resistant: D – Preclinical teniposide Resistant : D
TOP2A amplification	Rectal Cancer	TOP2A amplification	Rectal Cancer	teniposide Resistant: D – Preclinical teniposide Resistant : D	teniposide Resistant: D – Preclinical teniposide Resistant : D